Skip to content

    Gland Pharma

    GLANDGood
    Healthcare·5 Aug 2025
    Management Summary

    Gland Pharma delivered a strong start to FY26, characterized by a significant turnaround in its Cenexi subsidiary and robust margin expansion in the base business. The company is aggressively pivoting towards complex injectables and the GLP-1 market, with substantial capacity expansions underway. Despite some volatility in Enoxaparin supplies and seasonal shutdowns expected in Q2 for Cenexi, management remains confident in achieving mid-teen growth for the US market and maintaining consolidated margins in the 24-25% range.

    Highlights

    7
    • Consolidated Revenue reached ₹15,056 million, representing a 7% YoY growth.

    • Consolidated EBITDA grew 39% YoY to ₹3,678 million, with margins expanding to 24% from 19%.

    • Net Profit (PAT) surged 50% YoY to ₹2,155 million, driven by improved base business margins.

    • Cenexi achieved EBITDA breakeven (€0.9 million) for the first time since acquisition on revenue of €48 million.

    • US Revenue stood at ₹7,443 million (49% of total), supported by 9 new product launches including Epinephrine and Acetaminophen bags.

    • Cartridge capacity expansion is on track to reach 140 million units by March 2026 to support GLP-1 demand.

    • R&D expenditure was ₹460 million, representing 4.4% of base business revenue.

    What Changed1

    vs Q2 FY26

    Risks discussed3 → 4 (+1)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue15,056 Mn+7.0%YoY
    2. 02EBITDA3,678 Mn+39%YoY
    3. 03EBITDA Margin24%
    4. 04PAT2,155 Mn+50%YoY
    5. 05R&D Spend460 Mn-5.9%YoY

    Segment breakdown

    USA
    7,443 Mn Revenue49% Revenue Share
    Other Regulated Markets
    34% Revenue Growth27% Revenue Share
    Rest of the World (RoW)
    2,978 Mn Revenue5% Revenue Growth
    Cenexi
    48 Mn Revenue0.9 Mn EBITDA80% Gross Margin
    List

    Guidance & targets

    5
    CategoryTargetPriority
    Margin
    Consolidated EBITDA Margin
    24-25%
    High
    Capacity
    Pen and Cartridge Capacity
    140 million units
    High
    Volume
    GLP-1 Supply Quantity
    20 million units
    Medium
    Revenue
    US Market Revenue Growth
    mid-teen
    Medium
    Profitability
    Cenexi EBITDA
    positive
    Medium

    Risks & concerns

    6
    RiskSeverity

    US Import Tariffs

    Potential for tariffs on pharma imports under a new US administration; management plans to pass costs to partners if implemented.Analyst acknowledged

    medium

    Cenexi Seasonal Volatility

    Q2 profitability for Cenexi will be lower due to the one-month summer shutdown in Europe.Management acknowledged

    low

    Regulatory Inspections

    Ongoing monitoring of CAPA plans following ANSM inspections at Cenexi sites; a new inspection occurred in July.Management acknowledged

    medium

    Enoxaparin Supply Timing

    Lumpy order patterns for Enoxaparin (₹70cr vs ₹130-140cr normal) can distort quarterly US growth figures.Both acknowledged

    low

    Areas of Evasion(2)

    • Specific pricing for GLP-1 fill-finish contracts (cited fixed conversion cost model but no numbers).
    • Specific revenue contribution from Liraglutide launches.

    Q&A highlights

    3

    “The 100 million capacity FAT is in September and installation in November... Wegovy will come in FY '30. So most of the initial [products, we] will be filing from that line.”

    Confirms the aggressive timeline for GLP-1 infrastructure and clarifies that major volumes from blockbuster drugs like Wegovy are a long-term play (FY30).

    asked by Saion Mukherjee, Nomura Securities

    2 min read5 chapters

    Detailed Narrative

    01

    Cenexi Reaches Critical EBITDA Breakeven

    After several quarters of negative performance, Cenexi achieved EBITDA breakeven in Q1 FY26 with a profit of €0.9 million on revenue of €48 million. This turnaround was driven by improved gross margins (80% vs 78% YoY) and price increases negotiated last year. Management highlighted that the Fontenay site has improved order shipments and reduced downtime, while the Herouville-Saint-Clair site benefited from new product launches like Encepur. While Q2 will see a seasonal dip due to summer shutdowns, the long-term trajectory is aimed at high single-digit or low-teen EBITDA margins.

    02

    Aggressive GLP-1 and Cartridge Capacity Expansion

    Gland is positioning itself as a major CDMO player in the GLP-1 space, currently operating a 40 million unit cartridge capacity. The company is adding another 100 million units of capacity, with the Factory Acceptance Test (FAT) scheduled for September and full commercial readiness by March/April 2026. Management expects to supply approximately 20 million units in FY27, primarily for the Liraglutide and Semaglutide markets. The new high-speed pen lines are capable of producing 160 to 200 pens per minute, offering significant throughput advantages over traditional vial filling.

    03

    US Market Dynamics and Pipeline Momentum

    The US market contributed ₹7,443 million, representing 49% of total revenue. Growth was supported by the launch of 9 new molecules during the quarter, including Epinephrine and Acetaminophen bags. Despite a temporary slowdown in Enoxaparin supplies (₹70 crores this quarter vs ₹130-140 crores normally), management maintained its full-year guidance of mid-teen growth for the US. Key upcoming catalysts include the launch of Dalbavancin in the September quarter and the continued rollout of the RTU (Ready-To-Use) infusion bag portfolio, which now has 14 approved products out of 20 filed.

    04

    Geographic Diversification Beyond the US

    Gland is successfully deepening its presence in non-US markets, with 'Other Regulated Markets' (Europe, Canada, Australia, NZ) growing 34% YoY to account for 27% of total revenue. The Rest of the World (RoW) segment saw a modest 5% increase to ₹2,978 million, but management believes this business can double over the next few years through portfolio optimization and activating dormant registrations. In India, the company is exploring inorganic opportunities to achieve significant growth, although it currently represents only 4% of total revenue.

    05

    R&D Strategy and Complex Injectables

    R&D remains a core pillar, with ₹460 million spent in Q1 (4.4% of base revenue). The company filed one ANDA and received nine approvals during the quarter. The complex injectables pipeline is expanding, with six products already launched and three more awaiting approval. Gland's co-development model now comprises 15 products, including seven 505(b)(2) submissions. Management is also making a strategic push into advanced formats like dual and triple chamber bags and microsphere bulk filling to maintain its competitive edge in large-scale injectable solutions.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.